Patents Assigned to CELLIX BIO PRIVATE LIMITED
-
Patent number: 10774059Abstract: The disclosures herein provide compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These compounds may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, intravenous, spray, parenteral, lozenge, solution, syrup, sachet, transdermal administration, or injection. Such compositions may be used to treatment of inflammation or its associated complications.Type: GrantFiled: June 19, 2019Date of Patent: September 15, 2020Assignee: Cellix Bio Private LimitedInventor: Mahesh Kandula
-
Publication number: 20200190040Abstract: The disclosures herein provide compounds of formula I, formula II, formula III, formula IV, formula V and formula VI or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of gastrointestinal polyps or its associated complications.Type: ApplicationFiled: April 19, 2017Publication date: June 18, 2020Applicant: CELLIX BIO PRIVATE LIMITEDInventor: Mahesh Kandula
-
Publication number: 20190350877Abstract: The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI, formula XII, formula XIII, formula XIV and formula XV and the methods for the treatment of chronic pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of chronic pain.Type: ApplicationFiled: April 19, 2017Publication date: November 21, 2019Applicant: CELLIX BIO PRIVATE LIMITEDInventor: Mahesh Kandula
-
Publication number: 20190292171Abstract: The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII and formula VIII and, the methods for the treatment of cancer and infectious diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of cancer, neoplasm, infections and skin diseases.Type: ApplicationFiled: May 12, 2017Publication date: September 26, 2019Applicant: CELLIX BIO PRIVATE LIMITEDInventor: Mahesh Kandula
-
Publication number: 20190177267Abstract: The disclosures herein provide compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI, formula XII, formula XIII, formula XIV and formula XV or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, suppository, transdermal, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of irritable bowel syndrome (IBS), inflammatory bowel diseases or its associated complications.Type: ApplicationFiled: April 19, 2017Publication date: June 13, 2019Applicant: CELLIX BIO PRIVATE LIMITEDInventor: Mahesh Kandula
-
Patent number: 10227301Abstract: The invention relates to the compounds of formula I, formula II, formula III, formula IV and formula V or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV or formula V and methods for the treatment of inflammation and pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of pain, oral mucosal inflammatory or oral infectious diseases.Type: GrantFiled: May 7, 2015Date of Patent: March 12, 2019Assignee: Cellix Bio Private LimitedInventor: Mahesh Kandula
-
Patent number: 10208014Abstract: The invention relates to valproic acid derivatives or pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of valproic acid derivatives, and methods for treating or preventing neurological disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of epilepsy, bipolar disorder, migraine, schizophrenia, depression, Alzheimer's disease, cancer, HIV and familial adenomatous polyposis.Type: GrantFiled: November 5, 2014Date of Patent: February 19, 2019Assignee: CELLIX BIO PRIVATE LIMITEDInventor: Mahesh Kandula
-
Patent number: 9988340Abstract: The invention relates to the compounds of formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula II; and methods for treating or preventing multiple sclerosis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of neurodegenerative diseases and other inflammatory diseases.Type: GrantFiled: July 6, 2015Date of Patent: June 5, 2018Assignee: CELLIX BIO PRIVATE LIMITEDInventor: Mahesh Kandula
-
Patent number: 9932294Abstract: The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing multiple sclerosis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of multiple sclerosis and psoriasis.Type: GrantFiled: August 20, 2015Date of Patent: April 3, 2018Assignee: CELLIX BIO PRIVATE LIMITEDInventor: Mahesh Kandula
-
Patent number: 9840472Abstract: The invention relates to the compounds of formula I, formula II, formula III and formula IV or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III or formula IV and methods for the treatment of mucositis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of mucositis and oral mucosal inflammatory or oral infectious diseases.Type: GrantFiled: August 3, 2015Date of Patent: December 12, 2017Assignee: CELLIX BIO PRIVATE LIMITEDInventor: Mahesh Kandula
-
Patent number: 9771355Abstract: The invention relates to the compounds of formula I and formula Ia or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of formula I or formula Ia; and methods for treating or preventing epilepsy, seizures and convulsions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of epilepsy, seizures and convulsions.Type: GrantFiled: February 20, 2015Date of Patent: September 26, 2017Assignee: CELLIX BIO PRIVATE LIMITEDInventor: Mahesh Kandula
-
Patent number: 9765020Abstract: The invention relates to the compounds of related compounds, or pharmaceutically acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of mucositis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of mucus diseases related to painful inflammation and ulceration of the digestive tract lining and in the mouth.Type: GrantFiled: May 19, 2013Date of Patent: September 19, 2017Assignee: CELLIX BIO PRIVATE LIMITEDInventor: Mahesh Kandula
-
Patent number: 9738631Abstract: The invention relates to the compounds of formula I and formula IA or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I and formula IA; and methods for treating or preventing neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of epilepsy, bipolar disorder, trigeminal neuralgia, attention-deficit hyperactivity disorder (ADHD), schizophrenia, neuropathic pain, seizures, bipolar disorder, mania, phantom limb syndrome, complex regional pain syndrome, paroxysmal extreme pain disorder, neuromyotonia, intermittent explosive disorder, borderline personality disorder, Myotonia congenita and post-traumatic stress disorder.Type: GrantFiled: January 28, 2013Date of Patent: August 22, 2017Assignee: CELLIX BIO PRIVATE LIMITEDInventor: Mahesh Kandula
-
Patent number: 9725404Abstract: The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of salts of formula I or formula II; and methods for treating or preventing multiple sclerosis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of neurodegenerative diseases and psoriasis.Type: GrantFiled: January 7, 2015Date of Patent: August 8, 2017Assignee: CELLIX BIO PRIVATE LIMITEDInventor: Mahesh Kandula
-
Patent number: 9670153Abstract: The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing inflammation and lipid disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of hypertriglyceridemia, steatohepatitis, cystinosis and inflammatory diseases.Type: GrantFiled: August 17, 2013Date of Patent: June 6, 2017Assignee: CELLIX BIO PRIVATE LIMITEDInventor: Mahesh Kandula
-
Compositions and methods for the treatment of neuromuscular disorders and neurodegenerative diseases
Patent number: 9642915Abstract: The invention relates to the compound of or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for treating or preventing neuromuscular disorders and neurodegenerative diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, or parenteral-administration, or syrup, or injection. Such compositions may be used to treatment or management of neuromuscular disorders and neurodegenerative diseases such as Parkinson's disease, scleroderma, restless leg syndrome, hypertension and gestational hypertension.Type: GrantFiled: March 21, 2013Date of Patent: May 9, 2017Assignee: CELLIX BIO PRIVATE LIMITEDInventor: Mahesh Kandula -
Patent number: 9624168Abstract: The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing inflammation and lipid disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of hypertriglyceridemia, steatohepatitis, cystinosis and inflammatory diseases.Type: GrantFiled: August 17, 2013Date of Patent: April 18, 2017Assignee: CELLIX BIO PRIVATE LIMITEDInventor: Mahesh Kandula
-
Patent number: 9580383Abstract: The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing multiple sclerosis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of neurodegenerative diseases and other neuro-inflammatory diseases.Type: GrantFiled: November 5, 2014Date of Patent: February 28, 2017Assignee: CELLIX BIO PRIVATE LIMITEDInventor: Mahesh Kandula
-
Patent number: 9573927Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of severe pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of chronic pain, generalized pain disorders, leukemia, cancer, chronic pain, chemotherapy induced pain, epilepsy, migraine, neuropathic pain, post herpetic neuralgia, neuralgia, pain, drug addiction, detoxification of drugs, Alzheimer's disease, multiple sclerosis, multiple sclerosis, restless legs syndrome (RLS), cluster headache, depression, fibromyalgia, amyotrophic lateral sclerosis (ALS), convulsions, partial seizures, mood-stabilizing agent and bipolar disorder.Type: GrantFiled: February 4, 2013Date of Patent: February 21, 2017Assignee: CELLIX BIO PRIVATE LIMITEDInventor: Mahesh Kandula
-
Patent number: 9522884Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for treating or preventing metabolic disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be also used to the treatment of diabetes, lipid peroxidation, hypertriglyceridemia, metabolic disorders, free radical generated due to reactive oxygen and carbonyl groups, ionizing radiation, advanced glycation end products, kidney disease, renal complications and kidney stone disease.Type: GrantFiled: February 1, 2013Date of Patent: December 20, 2016Assignee: CELLIX BIO PRIVATE LIMITEDInventor: Mahesh Kandula